CClinicalTrials.gg
TerminatedNCT01320475Updated Sep 23, 2016

Epidural Levobupivacaine-sufentanil Versus Epidural Levobupivacaine and Intravenous Ketamine

A Phase 4 interventional study of Sufentanil and Ketamine in Thoracic Surgery, sponsored by Hopital Foch. Terminated at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-23.

Sponsored by Hopital Foch · Phase 4, Interventional, and Treatment

Why this study was terminated
Difficulty of Recruitment
Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Thoracic epidural analgesia is often proposed to thoracotomized patients. A local anesthetic and an opioid are generally associated to produce an epidural analgesia. However, opioid epidural administration is frequently associated with adverse effects as nausea, vomiting, urinary retention, ... On the other hand, iv ketamine has been demonstrated to be an effective analgesic.

The purpose of the study is to compare the epidural administration of levobupivacaine and sufentanil or the epidural administration of levobupivacaine associated with the iv administration of ketamine.

02

Conditions studied

  • Thoracic Surgery

Keywords

  • thoracic epidural analgesia
  • epidural opioid
  • ketamine
  • adverse effect
03

In context

Lead sponsor

Hopital Foch is the lead sponsor of 208 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • age between 18 and 75 yrs
  • class ASA I, II or III
  • lung surgery

Exclusion criteria

Exclusion Criteria:

  • Contra-indication to the achievement of epidural analgesia
  • Preoperative chronic pain,
  • Contra-indication to ketamine
  • Hypersensitivity to ketamine or any excipients
  • Uncontrolled hypertension,
  • Stroke
  • Heart failure
  • Hepatic porphyria
  • Contra-indication to sufentanil
  • Hypersensitivity to sufentanil, opioids or any excipients
  • Treatment with an opioid agonist-antagonist,
  • Contra-indication to levobupivacaine
  • Hypersensitivity to levobupivacaine, local anesthetics of the amide or any excipients
  • Hypotension, shock
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    iv Ketamine

    Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)

    Drug: Ketamine

  • Active comparator
    Sufentanil

    Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)

    Drug: Sufentanil

Interventions

  • DrugSufentanil

    Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)

  • DrugKetamine

    Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)

06

What researchers measure

Primary outcomes

  1. Occurrence of an adverse event due to the analgesic protocol

    Time frame: one week

  2. Efficacy of the analgesic regimen

    Time frame: third postoperative day

Secondary outcomes

  1. postoperative rehabilitation

    Time frame: two weeks

  2. postoperative complications (pulmonary, others)

    Time frame: one month

  3. length of stay

    Time frame: one month

  4. patient's satisfaction

    Time frame: sortie de l'hopital

  5. Occurence of a chronic pain

    Time frame: end the first postoperative year

07

Study locations

1 site
  • Hopital Foch
    Suresnes, 92150, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01320475
Lead sponsor
Hopital Foch
Responsible party
Sponsor
First posted
Mar 22, 2011
Start date
Sep 2010
Primary completion
Jul 2011
Completion
Jul 2011
Last update
Sep 23, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion